Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared Philippe Aftimos’s, Director of the Innovative Therapies Clinic at Jules Bordet Institute, post on X, adding:
“Ovarian function suppression is arguably the most important advancement for ER+ young women with breast cancer, markedly reducing recurrence.
Now more trials on how to support side effects for these women thrown into early menopause.”
Quoting Philippe Aftimos’s post:
Title: Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
Author: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Other articles featuring Sarah Sammons and Philippe Aftimos on OncoDaily.